Established in 2015, Cyclone is a well-known RPA software and solution provider in China. The main business is to develop and sell AI software products with independent copyright and intellectual property rights: Cyclone RPA (Robotic Process Automation). Cyclone RPA is widely used in banking, securities, insurance, government, energy, manufacturing, medical, power and other industries. Headquartered in Shanghai, Cyclone currently has branches and offices in dozens of cities such as Beijing, Shenzhen, Guangzhou, Shenyang, Harbin, and its commercialization footprint has expanded beyond Greater China to Japan and Southeast Asia.
Based on leading indoor unmanned driving technology, Standard Robots is committed to cooperating with flexible mobile robot products and dispatching systems to build a “factory-warehouse-distribution” digital logistics infrastructure for global high-end manufacturing factories and warehouses.
Standard Robots has been deeply involved in the high-end manufacturing industry in China, and has the largest market share in 3C manufacturing. The products have been recognized by customers in Japan, the United States and other countries internationally. In the future, Standard Robots will expand the logistics data link of the entire manufacturing park based on 5G, and continue to expand overseas.
Mech-Mind Robotics is a well-known “AI+3D+Intelligent” industrial robot solution provider in China. It is a high-tech enterprise focusing on the R&D, production and sales of software and hardware products in the 3D vision field.
Mech-Mind was founded in October 2016 by a team of returnees from Tsinghua University, who are dedicated to empowering industrial robots with intelligence. Mech-Mind is headquartered Beijing for R&D, in Shanghai for Sales and Deployment, and has branches and offices in Shenzhen, Qingdao, Changsha, Munich, Germany and other cities.
METiS Pharmaceuticals is a discovery technology and therapeutics company that has the potential to drive best-in-class drug assets in a wide range of therapeutic areas.
By integrating machine learning, quantum simulation, and high-throughput experimentation, we enable scientists to rapidly, comprehensively, and intelligently develop novel drug candidates.